190 related articles for article (PubMed ID: 21351089)
1. Serum antiglycan antibody detection of nonmucinous ovarian cancers by using a printed glycan array.
Jacob F; Goldstein DR; Bovin NV; Pochechueva T; Spengler M; Caduff R; Fink D; Vuskovic MI; Huflejt ME; Heinzelmann-Schwarz V
Int J Cancer; 2012 Jan; 130(1):138-46. PubMed ID: 21351089
[TBL] [Abstract][Full Text] [Related]
2. Naturally occurring anti-glycan antibodies binding to Globo H-expressing cells identify ovarian cancer patients.
Pochechueva T; Alam S; Schötzau A; Chinarev A; Bovin NV; Hacker NF; Jacob F; Heinzelmann-Schwarz V
J Ovarian Res; 2017 Feb; 10(1):8. PubMed ID: 28187738
[TBL] [Abstract][Full Text] [Related]
3. Does HE4 have a role as biomarker in the recurrence of ovarian cancer?
Plotti F; Capriglione S; Terranova C; Montera R; Aloisi A; Damiani P; Muzii L; Scaletta G; Benedetti-Panici P; Angioli R
Tumour Biol; 2012 Dec; 33(6):2117-23. PubMed ID: 22875782
[TBL] [Abstract][Full Text] [Related]
4. Blood Plasma-Derived Anti-Glycan Antibodies to Sialylated and Sulfated Glycans Identify Ovarian Cancer Patients.
Pochechueva T; Chinarev A; Schoetzau A; Fedier A; Bovin NV; Hacker NF; Jacob F; Heinzelmann-Schwarz V
PLoS One; 2016; 11(10):e0164230. PubMed ID: 27764122
[TBL] [Abstract][Full Text] [Related]
5. TEX19 promotes ovarian carcinoma progression and is a potential target for epitope vaccine immunotherapy.
Xu Z; Tang H; Zhang T; Sun M; Han Q; Xu J; Wei M; Yu Z
Life Sci; 2020 Jan; 241():117171. PubMed ID: 31843525
[TBL] [Abstract][Full Text] [Related]
6. Long-term clinical and immunological effects of p53-SLP® vaccine in patients with ovarian cancer.
Leffers N; Vermeij R; Hoogeboom BN; Schulze UR; Wolf R; Hamming IE; van der Zee AG; Melief KJ; van der Burg SH; Daemen T; Nijman HW
Int J Cancer; 2012 Jan; 130(1):105-12. PubMed ID: 21328579
[TBL] [Abstract][Full Text] [Related]
7. Identification of Tumor Antigens in Ovarian Cancers Using Local and Circulating Tumor-Specific Antibodies.
Da Gama Duarte J; Quigley LT; Young AR; Hayashi M; Miyazawa M; Lopata A; Mancuso N; Mikami M; Behren A; Meeusen E
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681879
[TBL] [Abstract][Full Text] [Related]
8. MAL2 and tumor protein D52 (TPD52) are frequently overexpressed in ovarian carcinoma, but differentially associated with histological subtype and patient outcome.
Byrne JA; Maleki S; Hardy JR; Gloss BS; Murali R; Scurry JP; Fanayan S; Emmanuel C; Hacker NF; Sutherland RL; Defazio A; O'Brien PM
BMC Cancer; 2010 Sep; 10():497. PubMed ID: 20846453
[TBL] [Abstract][Full Text] [Related]
9. Weapons ovarian epithelial tumors may use in immune escape: an immunohistochemical correlational study.
Hasby EA
Pathol Oncol Res; 2012 Apr; 18(2):509-18. PubMed ID: 22161157
[TBL] [Abstract][Full Text] [Related]
10. The O-Linked Glycome and Blood Group Antigens ABO on Mucin-Type Glycoproteins in Mucinous and Serous Epithelial Ovarian Tumors.
Vitiazeva V; Kattla JJ; Flowers SA; Lindén SK; Premaratne P; Weijdegård B; Sundfeldt K; Karlsson NG
PLoS One; 2015; 10(6):e0130197. PubMed ID: 26075384
[TBL] [Abstract][Full Text] [Related]
11. Upregulation of phosphorylated cofilin 1 correlates with taxol resistance in human ovarian cancer in vitro and in vivo.
Li M; Yin J; Mao N; Pan L
Oncol Rep; 2013 Jan; 29(1):58-66. PubMed ID: 23064469
[TBL] [Abstract][Full Text] [Related]
12. A novel multiple biomarker panel for the early detection of high-grade serous ovarian carcinoma.
Han C; Bellone S; Siegel ER; Altwerger G; Menderes G; Bonazzoli E; Egawa-Takata T; Pettinella F; Bianchi A; Riccio F; Zammataro L; Yadav G; Marto JA; Penet MF; Levine DA; Drapkin R; Patel A; Litkouhi B; Ratner E; Silasi DA; Huang GS; Azodi M; Schwartz PE; Santin AD
Gynecol Oncol; 2018 Jun; 149(3):585-591. PubMed ID: 29572027
[TBL] [Abstract][Full Text] [Related]
13. Comparison of printed glycan array, suspension array and ELISA in the detection of human anti-glycan antibodies.
Pochechueva T; Jacob F; Goldstein DR; Huflejt ME; Chinarev A; Caduff R; Fink D; Hacker N; Bovin NV; Heinzelmann-Schwarz V
Glycoconj J; 2011 Dec; 28(8-9):507-17. PubMed ID: 21948103
[TBL] [Abstract][Full Text] [Related]
14. LyGDI is a promising biomarker for ovarian cancer.
Zhen H; Yang S; Wu H; Wang S; Lv J; Ma L; Zhang X
Int J Gynecol Cancer; 2010 Apr; 20(3):316-22. PubMed ID: 20375790
[TBL] [Abstract][Full Text] [Related]
15. Soluble MUC1 and serum MUC1-specific antibodies are potential prognostic biomarkers for platinum-resistant ovarian cancer.
Budiu RA; Mantia-Smaldone G; Elishaev E; Chu T; Thaller J; McCabe K; Lenzner D; Edwards RP; Vlad AM
Cancer Immunol Immunother; 2011 Jul; 60(7):975-84. PubMed ID: 21461842
[TBL] [Abstract][Full Text] [Related]
16. IL17a and IL21 combined with surgical status predict the outcome of ovarian cancer patients.
Chen YL; Chou CY; Chang MC; Lin HW; Huang CT; Hsieh SF; Chen CA; Cheng WF
Endocr Relat Cancer; 2015 Oct; 22(5):703-11. PubMed ID: 26150382
[TBL] [Abstract][Full Text] [Related]
17. The clinicopathological significance of Bax and Bcl-2 protein expression with tumor infiltrating lymphocytes in ovarian carcinoma.
Yigit S; Demir L; Tarhan MO; Cabuk FK; Ellidokuz H; Erten C; Somali I; Dirican A; Cakalagaoglu F
Neoplasma; 2012; 59(5):475-85. PubMed ID: 22668011
[TBL] [Abstract][Full Text] [Related]
18. B7-H4 overexpression in ovarian tumors.
Tringler B; Liu W; Corral L; Torkko KC; Enomoto T; Davidson S; Lucia MS; Heinz DE; Papkoff J; Shroyer KR
Gynecol Oncol; 2006 Jan; 100(1):44-52. PubMed ID: 16256178
[TBL] [Abstract][Full Text] [Related]
19. CD105/Ki67 coexpression correlates with tumor progression and poor prognosis in epithelial ovarian cancer.
Liu P; Sun YL; Du J; Hou XS; Meng H
Int J Gynecol Cancer; 2012 May; 22(4):586-92. PubMed ID: 22266931
[TBL] [Abstract][Full Text] [Related]
20. EphA8 is a prognostic marker for epithelial ovarian cancer.
Liu X; Xu Y; Jin Q; Wang W; Zhang S; Wang X; Zhang Y; Xu X; Huang J
Oncotarget; 2016 Apr; 7(15):20801-9. PubMed ID: 26989075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]